SEDAR Interim Financial Statements
[ { "companyName": "Medicure Inc.", "reportingPeriodEnd": "2025-09-30", "reportStatus": "Unaudited", "auditorName": null, "auditorKeyMatters": [], "balanceSheet": { "asOf": "2025-09-30", "assets": { "currentAssets": { "cashAndCashEquivalents": 4118, "accountsReceivable": 4509, "inventories": 3899, "prepaidExpenses": 274, "totalCurrentAssets": 12800 }, "nonCurrentAssets": { "propertyAndEquipment": 1076, "intangibleAssets": 8336, "goodwill": 4417, "otherAssets": 94, "totalNonCurrentAssets": 13923 }, "totalAssets": 26723 }, "liabilities": { "currentLiabilities": { "accountsPayableAndAccruedLiabilities": 7904, "incomeTaxesPayable": 41, "currentPortionOfLeaseObligations": 480, "acquisitionPayable": 385, "holdbackPayable": 85, "totalCurrentLiabilities": 8895 }, "nonCurrentLiabilities": { "leaseObligations": 520, "totalNonCurrentLiabilities": 520 }, "totalLiabilities": 9415 }, "equity": { "shareCapital": 81014, "contributedSurplus": 11020, "accumulatedOtherComprehensiveLoss": -4959, "deficit": -69767, "totalEquity": 17308 }, "derivedMetrics": { "cashPerShare": 0.3946, "workingCapitalPerShare": 0.3742 } }, "incomeStatement": [ { "period": "three months ended September 30, 2025", "revenueNet": 8159, "costOfGoodsSold": 5386, "grossProfit": 2773, "sellingExpenses": 2199, "generalAndAdministrativeExpenses": 1167, "researchAndDevelopmentExpenses": 717, "totalExpenses": 4083, "otherIncomeLegalSettlement": null, "financeExpenseIncomeNet": 2, "foreignExchangeLossNet": 21, "netIncomeLossBeforeIncomeTaxes": -1333, "incomeTaxExpenseCurrent": 63, "netIncomeLoss": -1396, "otherComprehensiveIncomeExchangeDifferences": 362, "comprehensiveIncomeLoss": -1034, "earningsPerShareBasic": -0.13, "earningsPerShareDiluted": -0.13 }, { "period": "three months ended September 30, 2024", "revenueNet": 5153, "costOfGoodsSold": 2354, "grossProfit": 2799, "sellingExpenses": 1970, "generalAndAdministrativeExpenses": 1191, "researchAndDevelopmentExpenses": 795, "totalExpenses": 3956, "otherIncomeLegalSettlement": 1860, "financeExpenseIncomeNet": -18, "foreignExchangeLossNet": 46, "netIncomeLossBeforeIncomeTaxes": 675, "incomeTaxExpenseCurrent": -5, "netIncomeLoss": 680, "otherComprehensiveIncomeExchangeDifferences": -281, "comprehensiveIncomeLoss": 399, "earningsPerShareBasic": 0.07, "earningsPerShareDiluted": 0.07 }, { "period": "nine months ended September 30, 2025", "revenueNet": 20312, "costOfGoodsSold": 11261, "grossProfit": 9051, "sellingExpenses": 6161, "generalAndAdministrativeExpenses": 3526, "researchAndDevelopmentExpenses": 2028, "totalExpenses": 11715, "otherIncomeLegalSettlement": null, "financeExpenseIncomeNet": -52, "foreignExchangeLossNet": 105, "netIncomeLossBeforeIncomeTaxes": -2717, "incomeTaxExpenseCurrent": 159, "netIncomeLoss": -2876, "otherComprehensiveIncomeExchangeDifferences": -695, "comprehensiveIncomeLoss": -3571, "earningsPerShareBasic": -0.28, "earningsPerShareDiluted": -0.28 }, { "period": "nine months ended September 30, 2024", "revenueNet": 16012, "costOfGoodsSold": 6364, "grossProfit": 9648, "sellingExpenses": 5783, "generalAndAdministrativeExpenses": 3763, "researchAndDevelopmentExpenses": 2339, "totalExpenses": 11885, "otherIncomeLegalSettlement": 1860, "financeExpenseIncomeNet": -105, "foreignExchangeLossNet": 78, "netIncomeLossBeforeIncomeTaxes": -350, "incomeTaxExpenseCurrent": 136, "netIncomeLoss": -486, "otherComprehensiveIncomeExchangeDifferences": 430, "comprehensiveIncomeLoss": -56, "earningsPerShareBasic": -0.05, "earningsPerShareDiluted": -0.05 } ], "cashFlowStatement": [ { "period": "nine months ended September 30, 2025", "operatingActivities": -592, "investingActivities": -2177, "financingActivities": -304, "netChangeInCash": -3073, "cashBeginning": 7191, "cashEnd": 4118 }, { "period": "nine months ended September 30, 2024", "operatingActivities": -932, "investingActivities": -291, "financingActivities": -250, "netChangeInCash": -1473, "cashBeginning": 6369, "cashEnd": 4896 } ], "investmentsAndOtherAssets": [], "shareStructure": { "authorizedShares": "unlimited", "issuedShares": 10436313, "classesOfShares": ["common voting shares", "Class A common shares", "preferred shares"], "warrants": [], "options": [ { "number": 1189000, "exercisePrice": 1.24, "expiryDate": null } ], "rightsConvertibleInstruments": null }, "managementCompensation": { "currency": "CAD", "periods": [ { "period": "three months ended September 30, 2025", "salariesFeesAndBenefits": 181, "shareBasedPayments": 11, "total": 192 }, { "period": "three months ended September 30, 2024", "salariesFeesAndBenefits": 177, "shareBasedPayments": 25, "total": 202 }, { "period": "nine months ended September 30, 2025", "salariesFeesAndBenefits": 567, "shareBasedPayments": 49, "total": 616 }, { "period": "nine months ended September 30, 2024", "salariesFeesAndBenefits": 542, "shareBasedPayments": 84, "total": 626 } ], "namedIndividuals": [], "otherRelatedPartyTransactions": [ { "counterparty": "GVI-CDS", "description": "Clinical research services", "amount": 115, "period": "three months ended September 30, 2025" }, { "counterparty": "GVI-CDS", "description": "Business administration services", "amount": 21, "period": "three months ended September 30, 2025" }, { "counterparty": "GVI-CDS", "description": "Rental costs", "amount": 56, "period": "three months ended September 30, 2025" }, { "counterparty": "GVI-CDS", "description": "Information technology support services", "amount": 11, "period": "three months ended September 30, 2025" }, { "counterparty": "GVI-CDS", "description": "Clinical research services", "amount": 218, "period": "nine months ended September 30, 2025" }, { "counterparty": "GVI-CDS", "description": "Business administration services", "amount": 63, "period": "nine months ended September 30, 2025" }, { "counterparty": "GVI-CDS", "description": "Rental costs", "amount": 167, "period": "nine months ended September 30, 2025" }, { "counterparty": "GVI-CDS", "description": "Information technology support services", "amount": 32, "period": "nine months ended September 30, 2025" }, { "counterparty": "CanAm Bioresearch Inc.", "description": "Acquisition of patent and intellectual property for P5P Analogues", "amount": 100, "period": "year ended December 31, 2024" } ] }, "subsequentEvents": [] } ]